Ref ID: 19222
Author:
W. Duettmann, C. Koidl, L. Abdyli, B. Waitzl, B. Huber-Krassnitzer, J. Wagner, H. Schmidt, K. Troppan, T. Valentin, A. Wölfler, R. Krause, M. Hoenigl
Author address:
Graz, AT
Full conference title:
23rd European Congress of Clinical Microbiology and
Infectious Diseases
Date: 27 April 2014
Abstract:
Objectives: Serum galactomannan (GM) has been established as an an important method for diagnosing invasive aspergillosis (IA). In this study we evaluated performance of GM test in urine and compared results with those obtained in serum.
Methods: The study was performed from July-October 2012 in adult patients with underlying hematological malignancies hospitalized at the Department of Haematology at the Medical University of Graz in Austria and approved by the local ethics committee. Serum and urine samples were collected and tested twice weekly (always on the same day). For serum samples an optical density index (ODI) >=0.5 was considered positive.
Results: Each 192 serum and urine samples were collected in 35 patients. 15/192 (7.8%) serum samples in nine patients resulted positive. Sensitivity, specificity, PPV and NPV for different cut-offs from urine samples (compared to serum results) were as follows: 0.2 ODI: 25%, 93%, 24%, 93%; 0.15 ODI: 40%, 89%, 23%, 94%; 0.1 ODI: 56%, 84%, 21%, 95%. A cutoff of 0.15 ODI was chosen. 9/15 positive serum GM samples gave negative results in urine; 4 of those were derived from a patient with increasing positive serum GM levels in whom urine samples became positive with a 2 week delay. In 2 probable IA cases initially positive urine samples became negative under appropriate antifungal therapy while decreasing serum samples remained positive. 2 serum samples were considered false positives, 1 urine sample false negative. Urine resulted positive in 19/177 negative serum GM samples. 16 of those were considered false positives. In 1 patient (prob IA) urine GM resulted positive 3 days before serum GM; in 2 prob IA cases urine remained GM positive under appropriate antifungal therapy while serum samples were already negative again. Spearman-Rho correlation analysis revealed a significant positive correlation between serum and urine samples (p<0.001; p=0.27).
Conclusion: A significant positive correlation was found between urine and serum GM results. The 0.15 urine GM cut-off showed a high specificity but low sensitivity of 40% when compared to serum samples. Analyzing GM development over time and clinical data, however, the number of urine samples that were actually considered to have resulted falsely negative decreased to about half (5 samples from 2 patients). Further studies evaluating larger sample sizes of GM positive serum samples are needed before urine GM testing can be introduced into clinical routine.
Abstract Number: O160
Conference Year: 2013
Link to conference website: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=163156&XNSPRACHE_ID=2&XNKONGRESS_ID=180&XNMASK
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a